BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37852034)

  • 21. Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study.
    Koh SJ; Ohsumi S; Takahashi M; Fukuma E; Jung KH; Ishida T; Dai MS; Chang CH; Dalvi T; Walker G; Bennett J; O'Shaughnessy J; Balmaña J
    Breast Cancer; 2022 Jan; 29(1):92-102. PubMed ID: 34467476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer.
    Richau CS; Scherer NM; Matta BP; de Armas EM; de Barros Moreira FC; Bergmann A; Pereira Chaves CB; Boroni M; Dos Santos ACE; Moreira MAM
    Cancer Med; 2024 Feb; 13(3):e6729. PubMed ID: 38308422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.
    Sokolenko AP; Bogdanova N; Kluzniak W; Preobrazhenskaya EV; Kuligina ES; Iyevleva AG; Aleksakhina SN; Mitiushkina NV; Gorodnova TV; Bessonov AA; Togo AV; Lubiński J; Cybulski C; Jakubowska A; Dörk T; Imyanitov EN
    Breast Cancer Res Treat; 2014 Jun; 145(2):553-62. PubMed ID: 24800916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
    Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan.
    Cheng SM; Su YY; Chiang NJ; Wang CJ; Chao YJ; Huang CJ; Tsai HJ; Chen SH; Chang CY; Tsai CR; Li YJ; Yen CJ; Chuang SC; Chang JS; Shan YS; Hwang DY; Chen LT
    J Biomed Sci; 2024 Feb; 31(1):21. PubMed ID: 38350919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Castro E; Romero-Laorden N; Del Pozo A; Lozano R; Medina A; Puente J; Piulats JM; Lorente D; Saez MI; Morales-Barrera R; Gonzalez-Billalabeitia E; Cendón Y; García-Carbonero I; Borrega P; Mendez Vidal MJ; Montesa A; Nombela P; Fernández-Parra E; Gonzalez Del Alba A; Villa-Guzmán JC; Ibáñez K; Rodriguez-Vida A; Magraner-Pardo L; Perez-Valderrama B; Vallespín E; Gallardo E; Vazquez S; Pritchard CC; Lapunzina P; Olmos D
    J Clin Oncol; 2019 Feb; 37(6):490-503. PubMed ID: 30625039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer.
    Zhou C; Porter N; Borges M; Gauthier C; Ferguson L; Huang B; Nanda N; He J; Laheru D; Hruban RH; Goggins M; Klein AP; Roberts NJ
    Pancreatology; 2021 Aug; 21(5):938-941. PubMed ID: 33839031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.
    Reiner AS; Robson ME; Mellemkjær L; Tischkowitz M; John EM; Lynch CF; Brooks JD; Boice JD; Knight JA; Teraoka SN; Liang X; Woods M; Shen R; Shore RE; Stram DO; Thomas DC; Malone KE; Bernstein L; Riaz N; Woodward W; Powell S; Goldgar D; Concannon P; ; Bernstein JL
    J Natl Cancer Inst; 2020 Dec; 112(12):1275-1279. PubMed ID: 32119081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).
    Mahdi H; Hafez N; Doroshow D; Sohal D; Keedy V; Do KT; LoRusso P; Jürgensmeier J; Avedissian M; Sklar J; Glover C; Felicetti B; Dean E; Mortimer P; Shapiro GI; Eder JP
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34527850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
    Bodily WR; Shirts BH; Walsh T; Gulsuner S; King MC; Parker A; Roosan M; Piccolo SR
    PLoS One; 2020; 15(9):e0239197. PubMed ID: 32997669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pancreatic acinar cell carcinoma is associated with
    Kryklyva V; Haj Mohammad N; Morsink FHM; Ligtenberg MJL; Offerhaus GJA; Nagtegaal ID; de Leng WWJ; Brosens LAA
    Cancer Biol Ther; 2019; 20(7):949-955. PubMed ID: 31002019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic.
    Winter C; Nilsson MP; Olsson E; George AM; Chen Y; Kvist A; Törngren T; Vallon-Christersson J; Hegardt C; Häkkinen J; Jönsson G; Grabau D; Malmberg M; Kristoffersson U; Rehn M; Gruvberger-Saal SK; Larsson C; Borg Å; Loman N; Saal LH
    Ann Oncol; 2016 Aug; 27(8):1532-8. PubMed ID: 27194814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer.
    Chen B; Zhang G; Li X; Ren C; Wang Y; Li K; Mok H; Cao L; Wen L; Jia M; Li C; Guo L; Wei G; Lin J; Li Y; Zhang Y; Han-Zhang H; Liu J; Lizaso A; Liao N
    Aging (Albany NY); 2020 Feb; 12(4):3140-3155. PubMed ID: 32091409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.
    Schram AM; Colombo N; Arrowsmith E; Narayan V; Yonemori K; Scambia G; Zelnak A; Bauer TM; Jin N; Ulahannan SV; Colleoni M; Aftimos P; Donoghue MTA; Rosen E; Rudneva VA; Telli ML; Domchek SM; Galsky MD; Hoyle M; Chappey C; Stewart R; Blake-Haskins JA; Yap TA
    JAMA Oncol; 2023 Jan; 9(1):29-39. PubMed ID: 36394867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Germline genetic variants in men with prostate cancer and one or more additional cancers.
    Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
    Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
    Tung NM; Robson ME; Ventz S; Santa-Maria CA; Nanda R; Marcom PK; Shah PD; Ballinger TJ; Yang ES; Vinayak S; Melisko M; Brufsky A; DeMeo M; Jenkins C; Domchek S; D'Andrea A; Lin NU; Hughes ME; Carey LA; Wagle N; Wulf GM; Krop IE; Wolff AC; Winer EP; Garber JE
    J Clin Oncol; 2020 Dec; 38(36):4274-4282. PubMed ID: 33119476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing.
    Cheng DT; Prasad M; Chekaluk Y; Benayed R; Sadowska J; Zehir A; Syed A; Wang YE; Somar J; Li Y; Yelskaya Z; Wong D; Robson ME; Offit K; Berger MF; Nafa K; Ladanyi M; Zhang L
    BMC Med Genomics; 2017 May; 10(1):33. PubMed ID: 28526081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers.
    Nones K; Johnson J; Newell F; Patch AM; Thorne H; Kazakoff SH; de Luca XM; Parsons MT; Ferguson K; Reid LE; McCart Reed AE; Srihari S; Lakis V; Davidson AL; Mukhopadhyay P; Holmes O; Xu Q; Wood S; Leonard C; ; ; ; Beesley J; Harris JM; Barnes D; Degasperi A; Ragan MA; Spurdle AB; Khanna KK; Lakhani SR; Pearson JV; Nik-Zainal S; Chenevix-Trench G; Waddell N; Simpson PT
    Ann Oncol; 2019 Jul; 30(7):1071-1079. PubMed ID: 31090900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model.
    Lee AJ; Cunningham AP; Tischkowitz M; Simard J; Pharoah PD; Easton DF; Antoniou AC
    Genet Med; 2016 Dec; 18(12):1190-1198. PubMed ID: 27464310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
    Labidi-Galy SI; Rodrigues M; Sandoval JL; Kurtz JE; Heitz F; Mosconi AM; Romero I; Denison U; Nagao S; Vergote I; Parma G; Nøttrup TJ; Rouleau E; Garnier G; El-Balat A; Zamagni C; Martín-Lorente C; Pujade-Lauraine E; Fiévet A; Ray-Coquard IL
    Ann Oncol; 2023 Feb; 34(2):152-162. PubMed ID: 36564284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.